Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: Updated results of an ongoing phase II trial

This article has no abstract
Epistemonikos ID: 18a80edab5f32f5878c39d8836eb55286fdba759
First added on: Feb 05, 2025